Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Συνδρομές Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Ενδείξεις και αγωγές Βρείτε θεραπευτικές ενδείξεις και αγωγές για νόσους, συμπτώματα και ιατρικές πράξεις
Γνωρίζατε ότι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα

DERMOVATE Scalp application (2021)

Αναφορές

Βιβλιογραφική αναφορά

Στοιχεία εκδότη

Εκδότης GlaxoSmithKline UK
Διεύθυνση Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

Dermovate Scalp Application.

Qualitative and quantitative composition

Each 1 g contains 0.5 mg of clobetasol propionate (0.05% w/w).

Pharmaceutical form

Scalp application.

Therapeutic indications

Clobetasol propionate is a very potent topical corticosteroid which is indicated for use in short courses for conditions which do not respond satisfactorily to less active steroids. It is indicated for ...

Posology and method of administration

<b>Clobetasol propionate belongs to the most potent class of topical corticosteroids (Group IV) and prolonged use may result in serious undesirable effects (see section 4.4). If treatment with a local ...

Contraindications

Infections of the scalp. Hypersensitivity to the active substance or any of the excipients listed in section 6.1. Dermatoses in children under one year of age, including dermatitis.

Special warnings and precautions for use

Cases of osteonecrosis serious infections (including necrotizing fasciitis) and systemic immunosuppression (sometimes resulting in reversible Kaposis sarcoma lesions) have been reported with long-term ...

Interaction with other medicinal products and other forms of interaction

Co-administered drugs that can inhibit CYP3A4 (e.g. ritonavir and itraconazole) have been shown to inhibit the metabolism of corticosteroids leading to increased systemic exposure. The extent to which ...

Fertility, pregnancy and lactation

Pregnancy There are limited data from the use of clobetasol in pregnant women. Topical administration of corticosteroids to pregnant animals can cause abnormalities of foetal development (see section 5.3). ...

Effects on ability to drive and use machines

There have been no studies to investigate the effect of clobetasol on driving performance or the ability to operate machinery. A detrimental effect on such activities would not be anticipated from the ...

Undesirable effects

Adverse drug reactions (ADRs) are listed below by MedDRA system organ class and by frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100 and <1/10), uncommon (≥1/1,000 and <1/100), ...

Overdose

Symptoms Topically applied clobetasol may be absorbed in sufficient amounts to produce systemic effects. Acute overdosage is very unlikely to occur, however, in the case of chronic overdosage or misuse ...

Pharmacodynamic properties

<b>Pharmacotherapeutic group:</b> Corticosteroids, very potent (group IV) <b>ATC code:</b> D07AD Mechanism of action Topical corticosteroids act as anti-inflammatory agents via multiple mechanisms to inhibit ...

Pharmacokinetic properties

Absorption Topical corticosteroids can be systemically absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle ...

Preclinical safety data

Carcinogenesis / Mutagenesis Carcinogenesis Long-term animal studies have not been performed to evaluate the carcinogenic potential of clobetasol propionate. Genotoxicity Clobetasol propionate was not ...

List of excipients

Carbomer Isopropyl Alcohol Sodium Hydroxide Purified Water

Incompatibilities

None known.

Shelf life

Unopened: 24 months. Opened: 3 months.

Special precautions for storage

Do not store above 30°C. Keep container tightly closed when not in use. Contents are flammable. Keep away from fire, flame or heat. Do not leave Dermovate Scalp Application in direct sunlight.

Nature and contents of container

White High Density Polyethylene (HDPE) container with a white low density polyethylene (LDPE) nozzle and a white HDPE screw cap. Pack size: 25ml, 30ml, 100ml. Not all pack sizes may be marketed.

Special precautions for disposal and other handling

Patients should be advised to wash their hands after applying Dermovate Scalp Application. For detailed instructions for use refer to the Patient Information Leaflet in every pack. Do not use near a naked ...

Marketing authorization holder

Glaxo Wellcome UK Ltd trading as Glaxo Laboratories and/or GlaxoSmithKline UK, 980 Great West Road, Brentford, Middlesex, TW8 9GS

Marketing authorization number(s)

PL 10949/0046

Date of first authorization / renewal of the authorization

Date of first authorisation: 01 April 1993 Date of last renewal: 24 February 2010

Date of revision of the text

22 March 2021

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:

Μπορείτε να υποστηρίξετε τον Γαληνό στην αποστολή του να παρέχει δωρεάν έγκυρη πληροφόρηση για κάθε φάρμακο απενεργοποιώντας το Ad Blocker για αυτόν τον ιστότοπο.